Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Banzai - perhaps you could outline what they are as there is very little by the way of achievements which I was able to find in a senior role? Being appointed a NED of a start up does not mean a great deal. Bottom line is that I have a significant amount invested here as I can see that the work Ken James did in obtaining the relevant approvals was first class and we have the potential with Eroxon to do very well indeed.
That potential will only be optimised with a team of experienced, astute and professional executives. As a small company we rely principally on Barder and Hildreth for commercial and financial matters. Can you understand why I am so keen that we employ the correct calibre of people to turn this opportunity into a successful one as many companies at our stage of development, fail due to an inability to identify the right people to unlock value? I just hope that Lombard Odier are all over this and exerting pressure as they have the most skin in this game.
Are you going to mention Angela's other achievements and experience Bandit1? Why focus on only one part of Angelas resume?
Old school analysis? I think not.
I am old school Banzai and not convinced of the reliability, as yet, of generative AI. I recently asked my daughter for her thoughts (who has written a PHD thesis on this subject) and she remains somewhat sceptical so I take the lead from her. Oh well I will keep trying to find out whether Ms Hildreth is properly qualified to do this key job. By the way of anyone is interested, use Google to search Angela Hildreth, Perdu and you can see that she has been a finance manager in the hospitality industry in the past but nothing about her qualifications.
Chat GPT is open to all Bandit1, give it a try.
It worked for me, should for you too. GLA.
The Chat GPT BOT has scraped the media reports and told us what we already know. Perhaps you should ask it why we won’t turn a profit until 2025 despite signing multiple new deals and positive sales etc? I have asked the company if Ms Hidreth our Finance Director and COO is a qualified Chartered Accountant ( I suspect that she is not as I cannot find anything in my searches to confirm that she is, whereas with most listed plc’s it is quite easy to find references to an FD’s professional qualifications. They have failed to reply to this important question - why is that? The reason this is important is that we should have a CA in that role and crucially that we have made very serious gaffs in formal announcements to the market which should not and would not happen with the right calibre of senior people which IMO explains why we have dropped 40%. Can anyone help me out here that has better sources than I - perhaps you can ask Chat GBT Banzai and kindly share the response. Thanks and ATB.
With things being quiet I just asked chat GPT about Eroxon sales, and it couldn't have been more bullish. It forecast some big numbers for Q4 as well as this closing statement. GLA AI.
"...In summary, Eroxon is making a positive impact in the market, with successful launches, regulatory approvals, and strategic partnerships. 🚀🌟"
Why, thank you, Toli! Although I doubt the 'large buys' you're referring to are my tiddly top up this morning, right at the bottom! Lucky old me!
LOOKING VERY GOOD
Not many sells today yet…. Hopefully selling has halted……
I think the market makers have been taking up the slack and building liquidity. Share holders getting bored with slow progress, so reluctantly selling. Think the MM s know it’s only a matter of time before we have lift off!
They clearly don't use HL, Discoman - they'd have lost half their money in fees by now!
Why would the "mystery seller" take so long to sell chunks off shares and not just sell the lot in one chunk?
Once we have hit the bottom i think there are many people waiting to jump in
Not many sells yesterday....could the seller be done...then the only way is up......
UP tick coming. 40 pence first stop then 50 pence.....
Another £43k buy in and no sells
I aprecciate the frustration DaD. We should however offset that frustration with the fact that this product is a market disruptor and indeed making a new market, whilst hopefully impacting traditional remedies.
It's therfore difficult to be accurate with these market sizes you so desire as each region is developed. And as you know, any in accuracy gets shot down immediately.
I'm comfortable in the knowledge of the progress made and that an appropriate announcement will come when the time is right.
With this product, we will get a rise.
Why do the BOD still refuse to release informative RNS’s even after being called out on them? For one would not hurt to mention the market size in the regions acquired? The market size by value in the regions. At least then investor could estimate value to FUM. NOTHING AGAIN, clearly can’t teach an old dog new tricks! Get Rid of whoever is drafting these RNS’s fast.
Slow steady rise from here for as long as the MMs can sell above their buy price
I concur.
This deal and extension would have been scrutinized, double checked, re considered and finally given the nod of approval by people who have their jobs and company reputation to consider.
The decision wouldn't have been made without due diligence being done and current progress of Eroxon/ FUM being evaluated.
I see this as another step in the right direction.
Exactly,81.even if the intention to take up the extension option was in the pipeline a while ago,it will still have had to be sanctioned by the new owners,so a double level of approval in effect.
This is very good news. Not only is the product going to be driven by a much larger engine in South Americas now, it is a great endorsement of product that Acino is taking up the extension rights. They would have done their own due diligence prior to making this move. With Haleon in US and Acino in South Americas, should bode well for future. I can see confidence slowly returning.
Eroxon, not fortacin! sorry.
Interesting find,DRM.encouraging that M8 has expanded its involvement with fortacin so soon after its acquisition by Acino.
M8 Have been bought last month by a Swiss Pharma Acino Turnover More than Half a $Billion who in turn is mostly Abu Dhabi Sovereign wealth fund
https://www.thepharmaletter.com/article/acino-expands-latin-american-presence-in-m8-acquisition